Brooklyn Stock Today

BTX -  USA Stock  

USD 0.67  0.04  6.35%

Market Performance
0 of 100
Odds Of Distress
Less than 13
Brooklyn Immunotherapeuti is trading at 0.67 as of the 27th of May 2022; that is 6.35 percent up since the beginning of the trading day. The stock's open price was 0.63. Brooklyn Immunotherapeuti has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Brooklyn Immunotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2020 and ending today, the 27th of May 2022. Please note, there could be an existing legal relationship between Brooklyn Immunotherapeuti (BTX) and Lineage Cell Therapeutics (LCTX). Click here to learn more.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. The company has 52.04 M outstanding shares of which 2.79 M shares are currently shorted by investors with about 6.17 days to cover. More on Brooklyn Immunotherapeutics
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Brooklyn Immunotherapeuti Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Brooklyn Immunotherapeuti's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Brooklyn Immunotherapeuti or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Brooklyn Immunotherapeuti generated a negative expected return over the last 90 days
Brooklyn Immunotherapeuti has high historical volatility and very poor performance
Brooklyn Immunotherapeuti has some characteristics of a very speculative penny stock
Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN.
The company reported the last year's revenue of 3.45 M. Reported Net Loss for the year was (122.32 M) with profit before taxes, overhead, and interest of 4.69 M.
Brooklyn Immunotherapeutics has about 16.98 M in cash with (23.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Brooklyn Immunotherapeuti has a poor financial position based on the latest SEC disclosures
Roughly 42.0% of the company shares are held by company insiders
Latest headline from www.marketscreener.com: 2. LIQUIDITY AND MANAGEMENTS PLAN - Marketscreener.com
Brooklyn Immunotherapeuti Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Brooklyn Immunotherapeuti SEC Filings
Brooklyn Immunotherapeuti SEC Filings Security & Exchange Commission EDGAR Reports
Older SymbolNTN
Related EntityLCTX (Lineage Cell Therapeutics)
CEOMichael West  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Brooklyn Immunotherapeuti report their recommendations after researching Brooklyn Immunotherapeuti's financial statements, talking to executives and customers, or listening in on Brooklyn Immunotherapeuti's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Brooklyn Immunotherapeuti. The Brooklyn consensus assessment is calculated by taking the average forecast from all of the analysts covering Brooklyn Immunotherapeuti.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Brooklyn Immunotherapeuti based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Brooklyn Immunotherapeuti financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares46.7 M43.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted46.7 M43.3 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(24.1 M)(23.5 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets26.9 M32.4 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities20.6 M25.9 M
Significantly Down
Increasing
Slightly volatile
Current Assets20.2 M18.8 M
Significantly Up
Increasing
Slightly volatile
Current LiabilitiesM3.7 M
Significantly Up
Increasing
Very volatile
Total Debt3.8 M2.7 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.570.56
Fairly Up
Decreasing
Slightly volatile
Asset Turnover1.261.17
Significantly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Brooklyn Immunotherapeuti's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Brooklyn Immunotherapeuti's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Brooklyn Immunotherapeuti's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Brooklyn Immunotherapeuti's financial leverage. It provides some insight into what part of Brooklyn Immunotherapeuti's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Brooklyn Immunotherapeuti's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Brooklyn Immunotherapeuti deploys its capital and how much of that capital is borrowed.
Liquidity
Brooklyn Immunotherapeuti cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 2.72 M in debt with debt to equity (D/E) ratio of 0.42, which is OK given its current industry classification. Brooklyn Immunotherapeuti has a current ratio of 5.0, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brooklyn Immunotherapeuti until it has trouble settling it off, either with new capital or with free cash flow. So, Brooklyn Immunotherapeuti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brooklyn Immunotherapeuti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brooklyn to invest in growth at high rates of return. When we think about Brooklyn Immunotherapeuti's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(24.11 Million)Share
Brooklyn Immunotherapeutics (BTX) is traded on NYSEMKT Exchange in USA. It is located in 10355 Science Center Drive and employs 10 people. Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN. Brooklyn Immunotherapeuti is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with total capitalization of 37.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Brooklyn Immunotherapeuti's market, we take the total number of its shares issued and multiply it by Brooklyn Immunotherapeuti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Brooklyn Immunotherapeuti runs under Healthcare sector within Biotechnology industry. The entity has 52.04 M outstanding shares of which 2.79 M shares are currently shorted by investors with about 6.17 days to cover. Brooklyn Immunotherapeutics has about 16.98 M in cash with (23.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Check Brooklyn Immunotherapeuti Probability Of Bankruptcy
Ownership
Brooklyn Immunotherapeuti holds a total of fifty-two million fourty thousand outstanding shares. Brooklyn Immunotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Brooklyn Ownership Details

Brooklyn Stock Price Odds Analysis

What are Brooklyn Immunotherapeuti's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Brooklyn Immunotherapeuti jumping above the current price in 90 days from now is under 95%. The Brooklyn Immunotherapeutics probability density function shows the probability of Brooklyn Immunotherapeuti stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.7304 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Brooklyn Immunotherapeuti will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Brooklyn Immunotherapeuti is significantly underperforming DOW.
  Odds Below 0.67HorizonTargetOdds Above 0.67
5.88%90 days
 0.67 
94.10%
Based on a normal probability distribution, the odds of Brooklyn Immunotherapeuti to move above the current price in 90 days from now is under 95 (This Brooklyn Immunotherapeutics probability density function shows the probability of Brooklyn Stock to fall within a particular range of prices over 90 days) .

Brooklyn Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Brooklyn Immunotherapeuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Brooklyn Immunotherapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Brooklyn Immunotherapeuti's value.
InstituionSecurity TypeTotal SharesValue
Armistice Capital LlcCommon Shares5.5 M11.3 M
Blackrock IncCommon Shares2.4 M4.9 M
Citadel Advisors LlcCall Options108.7 K223 K
View Brooklyn Immunotherapeuti Diagnostics

Brooklyn Immunotherapeuti Historical Income Statement

Brooklyn Immunotherapeutics Income Statement is one of the three primary financial statements used for reporting Brooklyn's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brooklyn Immunotherapeuti revenue and expense. Brooklyn Immunotherapeuti Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022. View More Fundamentals

Brooklyn Stock Against Markets

Picking the right benchmark for Brooklyn Immunotherapeuti stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Brooklyn Immunotherapeuti stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Brooklyn Immunotherapeuti is critical whether you are bullish or bearish towards Brooklyn Immunotherapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Flow Index Now

   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Brooklyn Immunotherapeuti Corporate Directors

Brooklyn Immunotherapeuti corporate directors refer to members of a Brooklyn Immunotherapeuti board of directors. The board of directors generally takes responsibility for the Brooklyn Immunotherapeuti's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Brooklyn Immunotherapeuti's board members must vote for the resolution. The Brooklyn Immunotherapeuti board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Investing Brooklyn Immunotherapeutics

You need to understand the risk of investing before taking a position in Brooklyn Immunotherapeuti. The danger of trading Brooklyn Immunotherapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Brooklyn Immunotherapeuti is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Brooklyn Immunotherapeuti. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Brooklyn Immunotherapeuti is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.